Roche signs $15 billion antibody-drug conjugate deal with Hansoh
Chinese drugmaker Hansoh Pharmaceutical says the agreement covers a broad set of programs, a year after the companies' first collaboration of this kind.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
What happened
Roche has returned to Hansoh Pharmaceutical for a deal valued at $15 billion, a year after the two companies first partnered on antibody-drug conjugates. The agreement spans a broad portfolio of these programs, including two candidates already in preclinical development. Hansoh announced the deal in an October 19 release.
Why it matters
The deal signals that Roche is still looking to Chinese partners for new drugs.
Coverage
- Roche continues to look to China for new drugs (statnews.com)
- Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact (fiercebiotech.com)
More from Health
- Hackensack Meridian Health and Hunterdon Health agree to merge
- Putin's daughter predicts aging breakthroughs within 10 to 20 years
- Cardiologists urged to prescribe exercise for heart patients
- Pennsylvania measles outbreak tops 1,200 as CDC sends investigator
- AstraZeneca enlists Oracle to apply AI in drug trials
- Rising flu activity prompts vaccination calls in Colorado and Michigan